Cargando…
Glycol chitosan nanoparticles as specialized cancer therapeutic vehicles: Sequential delivery of doxorubicin and Bcl-2 siRNA
Conventional chemotherapy is plagued with adverse side effects because cancer treatments are subject to numerous variations, most predominantly from drug resistance. Accordingly, multiple or multistage chemotherapeutic regimens are often performed, combining two or more drugs with orthogonal and pos...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4217108/ https://www.ncbi.nlm.nih.gov/pubmed/25363213 http://dx.doi.org/10.1038/srep06878 |
_version_ | 1782342352963108864 |
---|---|
author | Yoon, Hong Yeol Son, Sejin Lee, So Jin You, Dong Gil Yhee, Ji Young Park, Jae Hyung Swierczewska, Maggie Lee, Seulki Kwon, Ick Chan Kim, Sun Hwa Kim, Kwangmeyung Pomper, Martin G. |
author_facet | Yoon, Hong Yeol Son, Sejin Lee, So Jin You, Dong Gil Yhee, Ji Young Park, Jae Hyung Swierczewska, Maggie Lee, Seulki Kwon, Ick Chan Kim, Sun Hwa Kim, Kwangmeyung Pomper, Martin G. |
author_sort | Yoon, Hong Yeol |
collection | PubMed |
description | Conventional chemotherapy is plagued with adverse side effects because cancer treatments are subject to numerous variations, most predominantly from drug resistance. Accordingly, multiple or multistage chemotherapeutic regimens are often performed, combining two or more drugs with orthogonal and possibly synergistic mechanisms. In this respect, glycol chitosan (GC)-based nanoparticles (CNPs) serve as an effective platform vehicle that can encapsulate both chemotherapeutics and siRNA to achieve maximal efficacy by overcoming resistance. Herein, DOX-encapsulated CNPs (DOX-CNPs) or Bcl-2 siRNA-encapsulated CNPs (siRNA-CNPs) exhibited similar physicochemical properties, including size, surface properties and pH sensitive behavior, regardless of the different physical features of DOX and Bcl-2 siRNA. We confirmed that the CNP platform applied to two different types of drugs results in similar in vivo biodistribution and pharmacokinetics, enhancing treatment in a dose-dependent fashion. |
format | Online Article Text |
id | pubmed-4217108 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | Nature Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-42171082014-11-06 Glycol chitosan nanoparticles as specialized cancer therapeutic vehicles: Sequential delivery of doxorubicin and Bcl-2 siRNA Yoon, Hong Yeol Son, Sejin Lee, So Jin You, Dong Gil Yhee, Ji Young Park, Jae Hyung Swierczewska, Maggie Lee, Seulki Kwon, Ick Chan Kim, Sun Hwa Kim, Kwangmeyung Pomper, Martin G. Sci Rep Article Conventional chemotherapy is plagued with adverse side effects because cancer treatments are subject to numerous variations, most predominantly from drug resistance. Accordingly, multiple or multistage chemotherapeutic regimens are often performed, combining two or more drugs with orthogonal and possibly synergistic mechanisms. In this respect, glycol chitosan (GC)-based nanoparticles (CNPs) serve as an effective platform vehicle that can encapsulate both chemotherapeutics and siRNA to achieve maximal efficacy by overcoming resistance. Herein, DOX-encapsulated CNPs (DOX-CNPs) or Bcl-2 siRNA-encapsulated CNPs (siRNA-CNPs) exhibited similar physicochemical properties, including size, surface properties and pH sensitive behavior, regardless of the different physical features of DOX and Bcl-2 siRNA. We confirmed that the CNP platform applied to two different types of drugs results in similar in vivo biodistribution and pharmacokinetics, enhancing treatment in a dose-dependent fashion. Nature Publishing Group 2014-11-03 /pmc/articles/PMC4217108/ /pubmed/25363213 http://dx.doi.org/10.1038/srep06878 Text en Copyright © 2014, Macmillan Publishers Limited. All rights reserved http://creativecommons.org/licenses/by/4.0/ This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder in order to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ |
spellingShingle | Article Yoon, Hong Yeol Son, Sejin Lee, So Jin You, Dong Gil Yhee, Ji Young Park, Jae Hyung Swierczewska, Maggie Lee, Seulki Kwon, Ick Chan Kim, Sun Hwa Kim, Kwangmeyung Pomper, Martin G. Glycol chitosan nanoparticles as specialized cancer therapeutic vehicles: Sequential delivery of doxorubicin and Bcl-2 siRNA |
title | Glycol chitosan nanoparticles as specialized cancer therapeutic vehicles: Sequential delivery of doxorubicin and Bcl-2 siRNA |
title_full | Glycol chitosan nanoparticles as specialized cancer therapeutic vehicles: Sequential delivery of doxorubicin and Bcl-2 siRNA |
title_fullStr | Glycol chitosan nanoparticles as specialized cancer therapeutic vehicles: Sequential delivery of doxorubicin and Bcl-2 siRNA |
title_full_unstemmed | Glycol chitosan nanoparticles as specialized cancer therapeutic vehicles: Sequential delivery of doxorubicin and Bcl-2 siRNA |
title_short | Glycol chitosan nanoparticles as specialized cancer therapeutic vehicles: Sequential delivery of doxorubicin and Bcl-2 siRNA |
title_sort | glycol chitosan nanoparticles as specialized cancer therapeutic vehicles: sequential delivery of doxorubicin and bcl-2 sirna |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4217108/ https://www.ncbi.nlm.nih.gov/pubmed/25363213 http://dx.doi.org/10.1038/srep06878 |
work_keys_str_mv | AT yoonhongyeol glycolchitosannanoparticlesasspecializedcancertherapeuticvehiclessequentialdeliveryofdoxorubicinandbcl2sirna AT sonsejin glycolchitosannanoparticlesasspecializedcancertherapeuticvehiclessequentialdeliveryofdoxorubicinandbcl2sirna AT leesojin glycolchitosannanoparticlesasspecializedcancertherapeuticvehiclessequentialdeliveryofdoxorubicinandbcl2sirna AT youdonggil glycolchitosannanoparticlesasspecializedcancertherapeuticvehiclessequentialdeliveryofdoxorubicinandbcl2sirna AT yheejiyoung glycolchitosannanoparticlesasspecializedcancertherapeuticvehiclessequentialdeliveryofdoxorubicinandbcl2sirna AT parkjaehyung glycolchitosannanoparticlesasspecializedcancertherapeuticvehiclessequentialdeliveryofdoxorubicinandbcl2sirna AT swierczewskamaggie glycolchitosannanoparticlesasspecializedcancertherapeuticvehiclessequentialdeliveryofdoxorubicinandbcl2sirna AT leeseulki glycolchitosannanoparticlesasspecializedcancertherapeuticvehiclessequentialdeliveryofdoxorubicinandbcl2sirna AT kwonickchan glycolchitosannanoparticlesasspecializedcancertherapeuticvehiclessequentialdeliveryofdoxorubicinandbcl2sirna AT kimsunhwa glycolchitosannanoparticlesasspecializedcancertherapeuticvehiclessequentialdeliveryofdoxorubicinandbcl2sirna AT kimkwangmeyung glycolchitosannanoparticlesasspecializedcancertherapeuticvehiclessequentialdeliveryofdoxorubicinandbcl2sirna AT pompermarting glycolchitosannanoparticlesasspecializedcancertherapeuticvehiclessequentialdeliveryofdoxorubicinandbcl2sirna |